Long-Term Tenofovir Alafenamide Study Confirms Eight-Year Safety and Efficacy for Hepatitis B Patients in China

New 8-year data confirms TAF as a safe, effective long-term treatment for Hepatitis B in China, showing reversible bone and kidney safety benefits.

By: AXL Media

Published: Apr 25, 2026, 8:43 AM EDT

Source: Information for this report was sourced from EurekAlert!

A Decisive Victory for Long-Term Viral Suppression in Chinese Cohorts

Medical researchers have concluded the longest investigation to date into the use of Tenofovir alafenamide (TAF) for chronic hepatitis B within the Chinese population, revealing remarkably durable outcomes. According to the study published in the Journal of Clinical and Translational Hepatology, more than 95 percent of participants who remained in the eight-year study achieved viral suppression when excluding missing data. This high rate of effectiveness underscores TAF as a cornerstone of long-term therapy, providing sustained biochemical and serological responses that are vital for managing a lifelong chronic infection.

The Comparative Safety Profile Against Traditional Antiviral Therapies

The clinical trials initially compared TAF against Tenofovir disoproxil fumarate (TDF), a common but historically taxing treatment for bone and renal health. For participants randomized to TAF from the beginning, estimated glomerular filtration rates and bone mineral density in the hip and spine remained remarkably stable over nearly a decade. The research highlights a critical advantage for the aging hepatitis B population, where co-morbidities related to kidney function and osteoporosis often complicate traditional antiviral regimens, necessitating a more refined pharmacological approach.

Evidence of Reversibility Following Treatment Switches

One of the most significant findings of this eight-year analysis is the potential for physical recovery after switching medications. Participants who were originally treated with TDF during the three-year double-blind phase experienced small declines in renal and bone parameters, which are known side effects of that specific compound. However, upon switching to open-label TAF for the subsequent five years, these safety markers showed measurable improvement. This suggests that the physiological damage associated with older tenofovir formulations is not necessarily permanent and can be mitigated through proactive therapeutic transitions.